Keyphrases
Neoantigen
85%
Tumor-infiltrating Lymphocytes
60%
Experienced Patients
50%
Colorectal Liver Metastases
50%
Nave
50%
Somatic mutation
50%
Neoantigen Identification
50%
Stomaphyx
50%
Metastatic Melanoma
50%
Neoadjuvant Therapy
50%
Gastrointestinal Cancer
50%
Preoperative Chemotherapy
50%
Endoscopic Gastric Plication
50%
Management Strategy
50%
Pancreatic Ductal Adenocarcinoma
50%
Improved Survival
50%
Node-positive
50%
Adoptive Cell Transfer
50%
Surgical Management
50%
Biomass Expansion
25%
Gene Products
25%
Tumor mutational Burden
21%
Common Cancers
20%
T Cells
19%
Autologous Tumors
19%
Colorectal Cancer
16%
Median Overall Survival
16%
Tumor
14%
Treatment Products
14%
T Cell Recognition
12%
Human Tumor Cells
12%
Immune Recognition
12%
Lymphocyte Subsets
12%
Non-synonymous mutation
12%
High-throughput
12%
Whole Exome Sequencing
12%
Mutation Rate
12%
Human Tumors
12%
Immunogenic
12%
Epithelial Cancer
12%
Mutant Protein
12%
Mutated Genes
12%
Cell-based
12%
FOLFIRINOX
11%
Overall Survival
11%
Node-positive Disease
11%
Node-negative
11%
Resection
11%
Pancreatic Cancer
11%
Disease Biology
8%
Medicine and Dentistry
Surgery
72%
Pancreas Adenocarcinoma
66%
Pancreas Cancer
64%
Organoid
50%
Liver Metastasis
50%
Personalized Medicine
50%
Colorectal Liver Metastasis
50%
Colorectal Cancer
50%
Treatment Response
50%
Biological Marker
50%
Plication
50%
Neoadjuvant Therapy
50%
Overall Survival
35%
Disease
26%
Roux-en-Y Gastric Bypass
20%
Somatic Mutation
16%
Next Generation Sequencing
16%
Ex Vivo
16%
Malignant Neoplasm
12%
Metastatic Carcinoma
12%
Cancer Diagnosis
12%
Operation Duration
12%
Clinical Trial
8%
Chemotherapy
8%
Tumor Marker
8%
Cytotoxic Chemotherapy
8%
Controlled Clinical Trial
8%
Endoscopic Biopsy
8%
Biopsy
8%
CA 19-9 Antigen
8%
Gemcitabine
7%
Patient Preference
7%
Pancreatectomy
7%
Postoperative Complication
7%
Neoadjuvant Chemotherapy
7%
Cancer Surgery
7%
Pathologist
7%
Functional Status
7%
Division
5%
Minimally Invasive Surgery
5%
Bariatric Surgery
5%
Invasive Procedure
5%
Immunology and Microbiology
Neoantigen
100%
Somatic Mutation
66%
Tumor-Infiltrating Lymphocytes
56%
Organoid
50%
Transfer Cell
50%
Immunotherapy
43%
T Cell
31%
Gene Product
25%
Next Generation Sequencing
16%
Tumor Cell
12%
Mutation Rate
12%
Whole Exome Sequencing
12%
Antigen Recognition
12%
CA 19-9 Antigen
8%
Tumor Antigen
6%
Immune Checkpoint Blockade
6%
Lymphocyte
6%
